MedTrace Logo

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

NCT05148871 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-08-07

No results posted yet for this study

Summary

A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)

Conditions

Interventions

BIOLOGICAL

Spikogen/Covax-19

Spikogen/Covax-19 is a recombinant spike protein vaccine formulated with Advax-CpG55.2 adjuvant

Sponsors & Collaborators

  • Australian Respiratory and Sleep Medicine Institute

    collaborator OTHER

  • Cinnagen

    collaborator INDUSTRY

  • Vaxine Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Dimitar Sajkov, MD, PhD · ARASMI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-02-23
Completion
2024-10-06

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05148871 on ClinicalTrials.gov